Kymera Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
200 Arsenal Yards Blvd Ste 230, Watertow...Phone Number
(857) 285-5300Website
www.kymeratx.comRevenue
$51.5 MillionStock Symbol
KYMRIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
2
1
About Kymera Therapeutics
Kymera Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Watertown, Massachusetts. The company specializes in research and development of targeted protein degradation therapeutics, a novel approach to address previously untreatable disease targets. Kymera's proprietary Pegasus platform facilitates the discovery of small molecule degraders that utilize the body's natural protein recycling machinery to eliminate disease-causing proteins. The company focuses on developing treatments for immune-inflammatory diseases, blood cancers, and solid tumors through its lead programs targeting IRAK4, IRAKIMiD, and STAT3 pathways. As a publicly traded company on Nasdaq, Kymera aims to become a fully integrated biopharmaceutical organization pioneering protein degrader medicines for conditions with significant unmet medical needs.Explore more
Kymera Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kymera Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Kymera Therapeutics recently announced quarterly report
Check out if Kymera Therapeutics is spiking on competitors!
Product Launch: Get notified when Kymera Therapeutics launches new products
Click to see if Kymera Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Kymera Therapeutics
Check if Kymera Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Kymera Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Kymera Therapeutics has new funding data
Recommended Actions
Find VP level buyers at Kymera Therapeutics
Find more new buyers
Compare Similar Companies to Kymera Therapeutics
Compare insights from companies similar to Kymera Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$50.7M
51-200
Private
-
1999
AO
Aram OganesianVice President, Clinical Pharmacology & Nonclinical Development
Company Profile Activity
Activity Insights
Kymera Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Kymera Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Kymera Therapeutics.
Kymera Therapeutics financials insights
Gather financial insights about Kymera Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$30M
2018
Series B
$65M
2020
Series C
$102M
Stock Offering
$199.8M
2022
Share Placement
$150M
Kymera Therapeutics Tech Stack
A closer look at the technologies used by Kymera Therapeutics
Most Recent Scoops
Person-Based
Medical Research, Clinical Operations
Person-Based
Pharmaceuticals, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Clinical Operations
Person-Based
Events, Clinical Operations
Kymera Therapeutics News & Media
Kymera's CEO Sold $6 Million in Stock After a 170% Run
This execution under a pre-scheduled Rule 10b5-1 plan follows 172% one-year stock surge.Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 programWhy Kymera Therapeutics Stock Popped This Week
It's getting quite the head start on an important clinical trial.Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
BROADEN2 enrollment completed nearly six months ahead of anticipated timelines
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kymera Therapeutics
Sign Up For FreeTo access detailed company insights
Kymera Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Watertown, Massachusetts. The company specializes in research and development of targeted protein degradation therapeutics, a novel approach to address previously untreatable disease targets. Kymera's proprietary Pegasus platform facilitates the d... Read More
